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ORIGINAL STUDY
Cross-reactivity in Grasses: Biochemical Attributes
Define Exemplar Relevance
Alan Bullimore, BSc, Toby Batten, MSc, Simon Hewings, BSc,
Karl Juergen Fischer von Weikersthal-Drachenberg, MD, and Murray Skinner, PhD
Introduction: Broad-spectrum grass pollen immunotherapies con-
tain large numbers of allergenic proteins from multiple species. The
principle of homologous grouping is used as a tool to assist in
the standardization of allergen immunotherapy. This study reviews
the principle of homologous grouping, questions what an exemplar
grass should be, and queries whether a 1-way system of inferring
homology is appropriate.
Methods: Grass pollens were extracted and analyzed using a variety
of techniques, including enzyme-linked immunosorbent assay,
Bradford protein assay, sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and quantitative analysis of Western blots.
Results: Variation in protein content, IgG, IgE, and Phl p 5
reactivity is evident among all grasses analyzed. There is signiﬁcant
evidence of similarity but also disparity consistent with variation
resulting from evolutionary change. Proprietary software called Gel
Electrophoresis Protein Proﬁle Analysis has been developed, which
highlights that each grass exhibits a greater than 55% similarity
measure; this is considered high similarity.
Discussion: None of the grass species examined display an identical
biological proﬁle. However, data indicate that there is a high degree
of homology, and Crested Dogstail is similar to each of the other 12
species analyzed; these levels of similarity can only be possible
because of molecular proﬁle and extensive sharing of epitopes.
These data are considered to be sufﬁcient to include Crested Dogstail
within the sweet grasses group of the Pooideae family; however, the
subtle differences in grasses also justify the inclusion of multiple
species to create a broad-spectrum immunotherapy.
Key Words: allergens, characterization, homology, grass,
immunotherapy
(WAO Journal 2012; 5:111–119)
Allergic sensitivity to grass pollen is responsible for 40% ofallergic cases worldwide.1 The group 1 and group 5 aller-
gens are considered as major allergens due to 90% and 65 to
85% of grass pollen allergic individuals possessing IgE reac-
tivity to each allergen, respectively.2 However, individuals
sensitized solely to minor allergens comprise a signiﬁcant
number of grass pollen allergic patients. One study found that
11% of patients were sensitized only to minor allergens,3
suggesting that although these allergens may be “minor”, they
are not “unimportant.”
The symptoms of allergy are the result of histamine
release, triggered by cross-linked allergen-speciﬁc IgE on the
surface of mast cells and basophils, along with other
inﬂammatory mediators, such as leukotrienes. The subsequent
recruitment of eosinophils is completed by the action of T-cell
cytokines, such as interleukin (IL)-4 and IL-5.
Speciﬁc immunotherapy (SIT) is recognized by the
World Health Organization, aside from allergen avoidance,
as the only treatment “that may affect the natural course of
allergic diseases.”4 The mechanism through which SIT oper-
ates has yet to be fully understood; however, SIT is thought to
function by the action of IL-12 inducing a shift from a TH2
response to a TH1 CD41 cytokine proﬁle. IL-10 and Trans-
forming Growth Factor (TGF)-b reduce the production of anti-
gen-speciﬁc IgE and proinﬂammatory cytokine release.5–15
Many immunotherapies are manufactured from natural
raw materials. These extracts are comprised of many
solubilized proteins, and because the use of multiple species
has been linked to potential treatment beneﬁt,16 multispecies
therapies contain a large number of allergenic proteins. This
multifarious nature invariably means that characterization is
more complex than that for a single-species product.
Criticism of the capacity to sufﬁciently characterize and
thus standardize a product17 risks a movement to simplify aller-
gen therapies, potentially leading to the exclusion of minor
allergens and multiple grass species. This could lead to a poten-
tial reduction in patient beneﬁt. Novel methods to characterize
immunotherapies, including mass spectrometry, amino acid
sequencing, and proteomics, are enabling complex allergen mix-
tures to be characterized in a way that was not possible before.
To facilitate allergenic species standardization, Lorenz
et al18 grouped species according to the principle of homologous
groups and allowed provision for the inclusion of more species as
further data became available. Recent ﬁndings have demonstrated
that the grasses of the Pooideae group, although cross-reactive
and homologous, contain varying amounts of major allergen.19
Moingeon et al19 conclude that this, coupled with the inclusion of
multiple species, mimics more natural exposure conditions.
A broad-spectrum product comprising 13 different
grass species such to better mimic the natural exposure
proﬁle alluded to by Moingeon et al (2008) has been
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investigated. This ultrashort course therapy is demonstrated to
be well tolerated and suitable for the treatment of allergic
rhinitis.20 Twelve of the constituent grass species are recog-
nized as homologous to Timothy grass (Phleum pratense) by
Lorenz et al.18 The thirteenth grass speciesdCrested Dogstail
(Cynosurus cristatus)dwas unable to be classiﬁed as homol-
ogous with the sweet grasses of the Poaceae family due to
lack of information available to the authors at the time.
Consequently, this work investigated a 13-grass prod-
uct mix to determine the allergenic and allergomic proﬁle of
the 13 component grass species using similarity assessments,
epitope blocking, in vitro analysis, and proprietary pattern–
matching algorithms. The data were used to conclude
whether, according to the criteria stated by Lorenz et al,18
Crested Dogstail can be considered homologous to the sweet
grasses group of the Pooideae family. This study additionally
reviews the principle of homologous grouping, questions
what an exemplar grass should be, and queries whether
a 1-way system of inferring homology is appropriate.
MATERIALS AND METHODS
Grass Pollen Extracts
Grass pollens were purchased from Allergon (Ängel-
holm, Sweden) and Pharmallerga (Lisov, Czech Republic).
Five percent single-pollen extracts were prepared by roller
mixing 2.31 g of pollen in 46.15 mL of phosphate extraction
buffer (1 mM Na2HPO4, 271.89 nM KH2PO4, 8.56 mM NaCl,
0.5% vol/vol phenol, 2 M HCl, and 2 M NaOH) at 2 to 88C
for 18 hours. A 13-grass mix was prepared by roller mixing
2.31 g of each of the 13 grasses in 600 mL of phosphate
extraction buffer at 2 to 88C for 18 hours. This was followed
by centrifugation at 3000g for 10 minutes to sediment the
solid material. Subsequently, the supernatant was clariﬁed
by passage through a 0.2-mm syringe ﬁlter (Millipore, Wat-
ford, United Kingdom). The ﬁltered extracts were then stored
at 2 to 88C until required for use.
Serum Pool Creation
Three serum pools were constructed with serum
sourced from PlasmaLabs (Everett, WA). The ﬁrst pool was
created with 8 grass-positive patients (1 female and 7 males,
of whom 6 were of white and 2 were African American
ethnicities). The second pool was created with 20 grass-
positive patients (7 female and 13 males, of whom 13 were of
white descent, 3 of Asian descent, 1 of Hispanic descent, and
1 of African American descent). The third pool was created
with the intention of blocking reactivity to Timothy grass
epitopes and composed of the 20-patient pool described
above plus the addition of native Timothy grass extract
prepared as above to a ﬁnal concentration of 1:5.
Sodium Dodecyl Sulfate–Polyacrylamide
Gel Electrophoresis
Aliquots of the pollen extracts were denatured by
heating at 1008C for 2 minutes in a sample buffer containing
sodium dodecyl sulfate. The proteins were then resolved on
a 10 to 20% Tris–HCl Criterion gel (Bio-Rad, Hemel Hemp-
stead, United Kingdom) and the gels electrophoresed accord-
ing to the manufacturer’s protocol. The separated proteins
were transferred onto polyvinyldiﬂuoride membranes using
a semidry apparatus (Bio-Rad). The membranes were then
washed and Western blotted as described below.
Western Blotting
A polyvinyldiﬂuoride membrane was blocked with 10%
milk diluent (KPL, Middlesex, United Kingdom) prepared in
Dulbecco phosphate-buffered saline (DPBS). The membranes
were then washed with phosphate-buffered saline–0.3%
Tween 20 and incubated overnight at 48C with the human
patient grass-positive sera pools prepared as above. All IgE
sera pools from grass allergic individuals were used at a 1:5
dilution (vol/vol in 5% milk diluent) and incubated overnight
at 2 to 88C. The membranes were washed again and incubated
with 1 mg/mL of biotinylated goat anti-human IgE (diluted
1:1000) for 1 hour at room temperature. After washing, the
membranes were incubated with 1 mg/mL of streptavidin–
peroxidase (Sigma, Poole, United Kingdom) diluted 1:1000
for 1 hour at room temperature. After a ﬁnal wash, the color
was developed with the addition of 1-component 3,39,5,59-
tetramethylbenzidine membrane peroxidase substrate (KPL,
Gaithersburg, MD). The color reaction was stopped by wash-
ing the membranes with distilled water.
Gel Electrophoresis Protein Profile Analysis
The Gel Electrophoresis Protein Proﬁle Analysis
(GEPPA) program (custom, in-house validated software) is
used as a numerical comparator that summarizes the overall
IgE reactive similarity between 2 samples run on sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and/or Western blotted with a similarity measure to
enable quantitative analysis of gel-based methods. Brieﬂy, an
image of a Western blot or SDS-PAGE gel is captured via the
Genegenius (Syngene, Cambridge, United Kingdom) and
imported into The Genetools program. Genetools program
identiﬁes the bands in each lane of the image and, via com-
parison with molecular weight markers, assigns a molecular
weight, band density, and peak height to each band within
each lane. This information is fed into the GEPPA program,
and based on band matching via molecular weight, peak
height, and band density, a similarity measure is generated
between the 2 samples. The use of this method to analyze gel-
based assays removes bias and subjectivity from what has
traditionally been a qualitative method. The program has been
validated to demonstrate robust and repeatable analysis of
data gathered from the Genetools software via use of cali-
brated molecular weight markers of known size and mobility.
IgE and IgG Enzyme-Linked Immunosorbent
Assay Potency Determination
Potency enzyme-linked immunosorbent assays (ELI-
SAs) were performed to measure the IgE and IgG reactivity of
the grass pollen extracts. IgE reactivity was determined by
competing solid-phase grass pollen extract with soluble
Bullimore et al WAO Journal  October 2012
112  2012 World Allergy Organization
samples for IgE antibodies. Brieﬂy, microtitre plates (Corning)
were incubated overnight at 2 to 88C with a freeze-dried
in-house reference preparation diluted in DPBS containing
magnesium chloride and calcium chloride. The plates were
washed with DPBS–Tween 20 and blocked with 1% bovine
serum albumin solution (Sigma) in coating buffer. After wash-
ing, samples were then loaded, followed by human anti-grass
IgE sera (pool of 8 patients as detailed above), and incubated
for 2 hours with continuous shaking at 208C. The plates were
washed once again and incubated with goat anti-human IgE
horseradish peroxidase. The color was then developed by add-
ing 3,39,5,59-tetramethylbenzidine peroxidase substrate (KPL).
The reaction was stopped with 1 M orthophosphoric acid
(Fisher, Loughborough, United Kingdom), and the plates were
read at 450 nm.
IgG reactivity was determined by measuring the group
1 content using an in-house competition ELISA in conjunction
with time-resolved ﬂuorescence. Brieﬂy, microtitre plates
(Thermo Fisher Scientiﬁc, United Kingdom) were coated with
50 mg/mL of staphylococcal protein-A in DPBS. After washing
the plate with DPBS–0.1% Tween 20, the wells were incubated
with rabbit anti-group 1 serum at 378C for 1 hour. This was
followed by the addition of a mixture of grass pollen extract
and Europium-labeled puriﬁed group 1 and incubated at 378C
for 1 hour 30 minutes. The plate was washed again and the
reaction developed with enhancement solution. The plate was
then read using a time-resolved ﬂuorescence spectrometer
(Perkin Elmer, Waltham, MA).
Phl p 5 Major Allergen Determination
Anti-Phl p 5 mAb 1D11 (Indoor Biotechnologies, Char-
lottesville, VA) diluted 1:1000 in 50 mM carbonate–bicarbonate
buffer was coated onto a NUNC Maxisorp plate and incubated
overnight at 2 to 88C. The plate was washed with 0.5% phos-
phate-buffered saline–Tween and blocked with 1% bovine serum
albumin diluted in 0.5% phosphate-buffered saline–Tween for
30 minutes. After washing as before, samples were loaded and
incubated for 1 hour. After a further wash, diluted biotinylated
anti-Phl p 5 mAb Bo 1 (Indoor Biotechnologies) was added to
the plate and incubated for 1 hour. Streptavidin–peroxidase
(0.25 mg/mL) diluted 1:1000 was added to the plate and incu-
bated for 30 minutes after washing. A ﬁnal wash was performed,
and the plates were developed by adding 100 mL of 1 mM 2,29-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) in 70
mM citrate–phosphate buffer containing H2O2. The plate was
read when the optical density at 405 nm reaches 2.0 to 2.4.
RESULTS
In Vitro Analysis of 13 Grasses
Protein Content
Thirteen 5% grass pollen extracts were analyzed for
total protein content via the Bradford protein assay.21 Total
protein content (Table 1) varied between each species. The
range of data runs from 1645.9 mg/mL for Cultivated Rye to
924 mg/mL for Sweet Vernal grass.
IgG Reactivity
Each species of grass demonstrated IgG binding and thus
reactivity (Table 1). A much greater degree of variation is evi-
dent than was found in the evaluation of protein content. Cul-
tivated Rye returned the lowest IgG potency of 190.10 quality
assurance units per milliliter (QAU/mL, an arbitrary in-house
unit) while the highest potency was 6412.00 QAU/mL reported
by Rye grass. The degree of variation observed is consistent
with what would be expected among species that are highly
cross-reactive yet contain unique epitopes.
IgE Reactivity
Thirteen grass pollen extracts were analyzed via an
in-house IgE inhibition ELISA where the large variation in
data observed in the IgG analysis is mirrored, albeit at a slightly
reduced level (Table 1). Sweet Vernal grass returned the lowest
IgE potency with a ﬁgure of 12.30 QAU/mL and FescueMeadow
returned the highest with a potency of 265.10 QAU/mL. The
variation in IgE is lower than that for IgG, suggesting greater
similarity among IgE epitopes in the grass species.
Phl p 5 Reactivity
Each grass sample demonstrated the presence of Phl p 5
reactive protein (Table 1). There is a large range in the data as
had been observed in the other potency methods. The lowest
reactivity was 2.45 mg/mL observed in Sweet Vernal grass and
the highest was 273.30 mg/mL in the False Oat grass. Mono-
clonal antibodies are very speciﬁc, and the assays they underpin
are typically highly repeatable. As there is similar variation in the
Phl p 5 assay and the non monoclonal assays, it could be inferred
that the variation observed is true and not due to assay variability.















Cultivated Rye grass 1645.90 190.10 22.60 114.20
Crested Dogstail grass 1595.30 1963.50 41.50 219.90
Yorkshire Fog grass 1332.60 4935.50 213.90 133.80
Brome grass 1027.10 193.85 20.10 19.66
False Oat grass 1636.70 2230.00 110.00 273.30
Foxtail Meadow grass 995.00 730.35 71.60 37.87
Timothy grass 1189.00 305.05 136.10 161.40
Fescue Meadow grass 1596.90 4785.50 265.10 231.00
Rye grass 1263.70 6412.00 157.20 205.00
Orchard grass 1191.80 1334.50 135.10 215.95
Meadow grass 1013.70 274.50 42.70 32.85
Sweet Vernal grass 924.90 1756.00 12.30 2.45
Bent grass 1251.00 1154.00 62.70 146.20
All 13 grasses mixed
(extracted separately)
1368.80 3865.00 186.30 117.60
All 13 grasses mixed
(extracted together)
1318.10 3762.50 197.10 120.40
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Graphical Interpretation of the In Vitro Data
The data in Table 1 have been graphically rendered
(Fig. 1) using radar graphs to illustrate the differences between
each species. Each radar graph is constructed such to present data
as a percent of the maximal value of the whole data set. The
charts highlight that 3 species (coded green) exhibit the greatest
concentration of IgE/IgG reactivity and Phl p 5 reactivity: Fescue
Meadow, Rye grass, and Yorkshire Fog grass. Five species are
FIGURE 1. Radar graphs illustrating the 4 in vitro analysis parameters of the 13 grass species.
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coded blue to indicate a relatively average amount of activity:
False Oat, Timothy, Cocksfoot, Bent grass, and Crested Dogstail.
The remaining 5 species (coded red) contain the lowest amounts
of active protein: Meadow grass, Brome grass, Foxtail Meadow,
Sweet Vernal, and Cultivated Rye.
The data (Table 1 and Fig. 1) detailing the effect of
extracting each of the 13 grasses together and extracting each
of the grasses separately and mixing highlight that there is no
difference in immunogenic or allergomic content of the
mixes.
FIGURE 2. Illustrating the blots, peaks,
and heights of the 13 grass species
Western blotted using human IgE serum.
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GEPPA Analysis of IgE Immunoblots of 13
Grass Species
Western blotting was used to visualize the IgE
reactive proteins of each of the 13 grass species. Figure 2
details the identiﬁed peaks and height reported by Gene
Genius software of each of the grass samples. Using GEPPA
to interpret these data, it is possible to quantitatively com-
pare multiple lanes and determine the degree of similarity
(Tables 2 and 3).
The calculated molecular weight of each band along
with band density and height are used by GEPPA to calculate
a numeral similarity measure useful in providing a quantitative
comparison of 2 samples. Each of the samples evaluated
by Western blotting were analyzed (Table 2) as a comparison
of the proﬁle of Crested Dogstail against the other 12
grass species.
There is signiﬁcant homology between the Crested
Dogstail grass and the other 12 grass species (Table 2). Each
grass exhibits a greater than 55% similarity measure, which
indicates that a signiﬁcant number of allergenic proteins have
been found to match. However, these data also indicate that
there are minor differences between species possibly attribut-
able to unique epitopes not shared among the species. The
mean similarity is 63.7%, and the variation is d ¼ 18.38 to
27.82 from the mean.
Table 3 details the GEPPA comparison when Timothy
grass is used as the comparator. The data broadly mirror those
seen in Table 2, where there is demonstrated homology and
similarity between the grass species, which is supportive of
grouping. However, Sweet Vernal grass is only 39.8% similar
to Timothy grass (even though they are considered homolo-
gous18), whereas it is 66.1% similar to Crested Dogstail
(Table 2). The mean similarity of 67.31% corresponds to that
found in Table 2; however, the variation is d ¼ 115.19 to
227.51, which is considerably more variable than the Crested
Dogstail comparison.
Epitope Specificity
A number of Western blots of each of the 13 grass
species (Table 4) were run to evaluate epitope speciﬁcity and
sharing using different sera pools. Human anti-grass IgE
serum was pooled with 5% Timothy native extract to block
Timothy grass epitopes and was used to probe one of the
gels.
Figure 3 illustrates the Western blot probed with sera
where there are no blocked epitopes (pool of 8 patients). As
has been previously demonstrated,22 there is clear evidence
of similar reactivity among the grasses, yet subtle differences
are evident illustrating the unique allergenic attributes pre-
viously discussed. The use of a serum pool blocked to Tim-
othy epitopes (Fig. 4) reveals unique epitopes present in each
grass species. There is no banding present in the lane con-
taining Timothy grass, demonstrating that the blocking was
effective, yet there is clear banding in each other grass spe-
cies, indicating IgE reactivity to epitopes not present in Tim-
othy grass.
Finally, Figure 5 illustrates the Western blot where
a serum pool composed of 20 grass allergic patients was used.
Epitope recognition, band density, and speciﬁcity are indis-
tinguishable from those present in Figure 3, where 8 patients
made up the pool.
TABLE 2. GEPPA Analysis Showing the Similarity Measure of








Crested Dogstail Colonial Bent 66.80 13.08
Crested Dogstail Brome 58.40 25.32
Crested Dogstail Orchard 72.10 18.38
Crested Dogstail False Oat 65.80 12.08
Crested Dogstail Fescue Meadow 59.10 24.62
Crested Dogstail Foxtail Meadow 61.70 22.02
Crested Dogstail Meadow 65.00 11.28
Crested Dogstail Rye Grass 55.90 27.82
Crested Dogstail Timothy 60.70 23.02
Crested Dogstail Sweet Vernal 66.10 12.38
Crested Dogstail Yorkshire Fog 67.70 13.98
Crested Dogstail Cultivated Rye 65.30 11.58
Similarity mean d 63.72 d
TABLE 3. GEPPA Analysis Showing the Similarity Measure of









Timothy Colonial Bent 77.70 110.39
Timothy Brome 82.50 115.19
Timothy Orchard 62.20 25.11
Timothy False Oat 62.80 24.51
Timothy Fescue Meadow 77.40 110.09
Timothy Foxtail Meadow 57.80 29.51
Timothy Meadow 72.30 14.99
Timothy Rye Grass 68.50 11.19
Timothy Crested Dogstail 60.70 26.61
Timothy Sweet Vernal 39.80 227.51
Timothy Yorkshire Fog 82.20 114.89




FIGURE 3. Demonstrating the IgE reactivity of each of the 13
grass species using a serum pool comprising 8 grass allergic
patients.
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DISCUSSION
It is proposed that, due in part to the varied species
geography, exposure conditions, and patient diversity, no
immunotherapeutic can treat all patients. Moingeon et al19
indicate that an immunotherapy consisting of multiple species
better reﬂects natural exposure conditions, and in work pub-
lished in 2011, Bullimore et al22 noted the same to be likely.
Grass pollens from 13 different species were extracted
under identical conditions and yielded different proﬁles in
terms of protein content, IgG, IgE, and Phl p 5 reactivity.
Sweet Vernal grass (Anthoxanthum odoratum) was found to
contain the least amount of protein of all the grasses tested,
the least amount of Phl p 5 major allergen reactivity, and
comparatively low levels of IgE and IgG reactive protein.
Conversely, Cultivated Rye (Secale cereale) was discovered
to contain the highest recorded amount of total protein, how-
ever exhibits similar low levels of IgG and IgE reactive
protein as that found in Sweet Vernal grass. These data
indicate that the differences in biological character are not
attributable to the ability to extract protein from the raw
material but rather from inherent differences between each
of the grasses.
No single grass species examined displays an identical
biological proﬁle (Fig. 1); of particular interest are the data
recorded for the considered exemplar grass of the Pooideae
family, Timothy. The data indicate comparatively lower con-
tent for protein, lower IgE and Phl p 5 reactivity, and there is
only a fraction of the IgG reactivity found in the other grass
species analyzed. A vigorous IgG response is implicated in
effective SIT,10 and these observations suggest that in thera-
pies consisting of only single species, the potential lack of
sufﬁcient IgG reactivity could impact effectiveness.
The differences in immunogenicity between each of the
5% (w/v) grass extracts are not directly comparable with
studies conducted on puriﬁed allergens nor samples where the
amount of allergen has been levelled across species. The low
IgG reactivity observed in Timothy grass compared with the
other species does not imply that Timothy is weakly IgG
reactive; merely that for a given amount of raw material, there
is less IgG reactive protein per gram. If some grass species
contain more immunogenic material per unit volume as these
data suggest, then it is possible to infer that patients exposed
to pollen from these species would, by default, be exposed to
more immunogenic material too.
The relative differences in IgE reactivity of each of the
analyzed grass species is interesting. Of the 13 grasses
analyzed, only Rye grass and Yorkshire Fog exhibit .50%
of the IgE reactivity of the grass with the most IgE reactivity,
Fescue Meadow grass. The remaining 10 species (including
the considered exemplar Timothy grass) possess#50% of the
IgE reactivity. IgE epitopes are recognized as the causative
agent of allergy; the relative differences seen in IgE reactivity
compared with protein content could be indicative of a pro-
pensity for more/less aggressive sensitization proﬁles. Should
a therapy be designed based on targeting a wide population of
sensitization proﬁles, it may be wise to consider immunother-
apy with multiple grass species.
This is corroborated by Figure 4 illustrating that the
use of sera with Timothy-speciﬁc epitopes blocked shows
signiﬁcant reactivity to each of the other grass species stud-
ied. This is indicative of unique epitopes present in the other
grass species that are not present in Timothy grass and not
solely indicative of cross-reactivity as speculated previously.
FIGURE 4. Demonstrating the IgE reactivity of each of the 13
grass species using a serum pool comprising 20 grass allergic
patients with all Timothy grass epitopes blocked.
TABLE 4. Identity of Grass Species in Each Lane in Western
Blots (Figures 3–5)
Lane Number Sample Identity














15 Molecular weight marker
16 Molecular weight marker
FIGURE 5. Demonstrating the IgE reactivity of each of the 13
grass species using a serum pool comprising 20 grass allergic
patients.
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Cross-reactivity is no doubt present; however, Figure 4
suggests that SIT using only Timothy grass may not treat
all grass-sensitive patients.
The in vitro analysis of 13 grass species indicates that
the use of multiple species could negate the need to include
high quantities of raw material to compensate for low yield
(which could potentially lead to high levels of nonreactive
material or complicated puriﬁcation methods) while main-
taining allergenic and cross-species reactivity.
Our present data can be used to highlight the impor-
tance of appropriate allergen mixes in diagnosis and in
immunotherapy. Diagnosis of allergic sensitization is com-
monly performed using skin prick testing. This, together with
the case history, is maintained as the current practical method
to determine suitability for SIT. The data herein regarding the
unique allergenic properties of certain grass species, sub-
stantiated by the description by Moingeon et al19 regarding
natural exposure conditions, suggest that allergen mixes could
offer advantages to diagnosis. Diagnosis using recombinant
allergens or a single species may lead to some patients sen-
sitized to minor allergens or alternate grasses being missed.
However, a diagnostic test comprised the 13 grass species
tested in this investigation could further cover the potential
patient population and result in fewer missed diagnoses.
GEPPA is a technique whereby the determined molec-
ular weight, band density, and peak height of separated
proteins are used to calculate a “similarity measure.” The
similarity measure is a quantitative means for the interpreta-
tion of SDS-PAGE/Western blot proﬁles. The development of
GEPPA was initiated out of a need for a repeatable nonbiased
method to compare different samples run using SDS-PAGE
and/or Western blotting. Conventional methods can be inﬂu-
enced by visual subjectivity and interpretation, so a method
that reduces this apparent bias would be advantageous. GEP-
PA is a validated technique that has been used to enable
instant comparison and reproducibility of reference material
compared with test samples and has been used in the present
study to compare the similarity of each of 13 grass species.
Western blots were generated using a pool of human patient
grass-positive sera.
Data indicate that there is a high degree of homology,
and Crested Dogstail is considered similar to each of the other
12 species (Table 2). Eight of the 12 grasses analyzed via
GEPPA against Crested Dogstail exhibited a similarity mea-
sure of .60% with the remaining 5 demonstrating a .55%
similarity measure. The similarity measure of Crested Dogstail
compared with Timothy is also comparable with the other
grass species (Table 3). Here, all species demonstrate a simi-
larity measure of.58% apart from Sweet Vernal grass (38%).
Aside from Crested Dogstail, each grass is considered
grouped; justiﬁcation for the inclusion of Crested Dogstail
into the sweet grasses group of the Pooideae family as deﬁned
by Lorenz et al18 is evident because of the close correlation of
the similarity measure of Crested Dogstail to the already
grouped species (Tables 2 and 3). The levels of similarity
can only be possible because of analogous molecular proﬁle
and extensive sharing of epitopes among the grass group,
which in itself could be considered justiﬁcation for the inclu-
sion of Crested Dogstail to the sweet grasses group.
These ﬁndings are corroborated by the work by
Bullimore et al,22 where homology between each of the 13
grass species used within a 13-grass immunotherapeutic via
mass spectrometry was demonstrated. The data established
structural homology and epitope sharing between species
consistent with criteria Lorenz et al,18 detail to be sufﬁcient
to enable the inclusion of crested dogstail within the sweet
grasses group of the Pooideae family.
Our ﬁndings illustrate that there is greater variation in
similarity measure when Timothy grass is used as the exemplar
grass species compared with when Crested Dogstail is used
(Tables 2 and 3, respectively). This correlates with the in vitro
data presented in this study, which opens questions as to
whether the current strategy for dealing with data extrapolation
from one species to another in terms of homologous groups
is appropriate.
Lorenz et al18 suggest that there are 2 grass species that
may act as the representative allergen source for the homol-
ogous group of sweet grasses of the Poaceae (Gramineae)
family (including those listed with reservations): Timothy or
Kentucky Bluegrass. We propose that, because of the homol-
ogy demonstrated by Lorenz et al18 in their proposal and
backed by our own ﬁndings,22 the principles of homologous
groups regarding the sweet grasses of the Poaceae (Grami-
neae) family be maintained albeit with the addition of Crested
Dogstail (C. cristatus) to the group.
However, we suggest that any member of the group
could act as the exemplar species based on biochemical
assessment, not just Timothy grass or Kentucky Bluegrass.
There is no biochemical justiﬁcation as to why it is acceptable
to infer data from Timothy grass on to Sweet Vernal grass but
not the other way round. In our suggested model of
homologous grouping, if species are determined to be
homologous, then any species can be the exemplar.
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